Cited by 162Extracellular vesicles in diseaseNanoparticle-Based Drug DeliveryBarrier Structure and Function Studies

Cell-derived nanovesicle-mediated drug delivery to the brain: Principles and strategies for vesicle engineering

Open access
Liang, Yujie, Iqbal, Zoya, Lu, Jianping, Wang, Jianhong, Zhang, Hao, Chen, Xi, Duan, Li, Xia, Jiang·2023·Molecular Therapy

Abstract

Developing strategies toward safe and effective drug delivery into the central nervous system (CNS) with improved targeting abilities and reduced off-target effects is crucial. CNS-targeted drug carriers made of synthetic molecules raise concerns about their biodegradation, clearance, immune responses, and neurotoxicity. Cell-derived nanovesicles (CDNs) have recently been applied in CNS-targeted drug delivery, because of their intrinsic stability, biocompatibility, inherent homing capability, and the ability to penetrate through biological barriers, including the blood-brain barrier. Among these CDNs, extracellular vesicles and exosomes are the most studied because their surface can be engineered and modified to cater to brain targeting. In this review, we focus on the application of CDNs in brain-targeted drug delivery to treat neurological diseases. We cover recently developed methods of exosome derivation and engineering, including exosome-like particles, hybrid exosomes, exosome-associated adeno-associated viruses, and envelope protein nanocages. Finally, we discuss the limitations and project the future development of the CDN-based brain-targeted delivery systems, and conclude that engineered CDNs hold great potential in the treatment of neurological diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2022.10.008

Cites

146 of 146 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Engineered exosomes carrying RVG-Lamp2b can efficiently cross the blood-brain barrier and deliver catalase mRNA, resulting in a reduction of 6-OHDA-mediated neuroinflammation in a mouse model of Parkinson's disease.

    “The designed exosome carrying RVG-Lamp2b was able to efficiently cross the blood–brain barrier (BBB) and deliver the catalase mRNA, resulting in a reduction of 6-OHDA-mediated neuroinflammation in a mouse model of Parkinson’s disease [101, 103].”
  • Two main approaches can be used to enhance targeting ability of exosomes: direct chemical modification or indirect genetic engineering.

    “Two main approaches can be used to enhance the targeting ability of exosomes for specific applications: direct modification of exosomes by chemical means or, indirect manipulation of the donor cells through genetic engineering techniques [89, 103, 118–120]”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [126]Mo J. Li M. Zinc sulfide-based hybrid exosome-coated autophagic flux-mediated hydrogen sulfide-sensitized PDT/chemotherapeutic synergistic nanoplatform for targeted treatment of glioblastoma stem-like cells in orthotopic mouse glioblastoma model Preprint at bioRxiv 2020

Cited by

Sorted by citations

Authors
Liang, Y., Iqbal, Z., Lu, J., Wang, J., Zhang, H., Chen, X., Duan, L., & Xia, J.
Affiliations
  • Shenzhen University (CN)
  • Shenzhen KangNing Hospital (CN)
  • State Key Laboratory of Digital Medical Engineering (CN)
  • Chinese University of Hong Kong (HK)
Corresponding author
  • Duan, Li
  • Xia, Jiang
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2023-05
Volume
31
Issue
5
Pages
1207-1224
ISSN
1525-0016 (ISSN-L)
OpenAlex
W4306393265
Cited by
162
References
146
Citations by year
2026: 31 · 2025: 54 · 2024: 44 · 2023: 33
FWCI
3.41
Type
journal article
Language
en
Open access
Locations
  • Molecular Therapy (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Innovation and Technology Commission
  • Shenzhen Science and Technology Innovation Committee
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Keywords
brain drug delivery, extracellular vesicles, exosomes, exosome engineering, blood-brain barrier, neurological disorders
MeSH terms
Extracellular Vesicles, Blood-Brain Barrier, Brain, Drug Delivery Systems, Exosomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review